Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00002892
Recruitment Status : Completed
First Posted : May 13, 2004
Last Update Posted : December 19, 2013
Information provided by:
National Cancer Institute (NCI)

No Study Results Posted on for this Study
Recruitment Status : Completed
Primary Completion Date : No date given
Actual Study Completion Date : December 2001
Publications of Results:
Hancock BW, Wheatley K, Harrison G, et al.: Aim high-adjuvant interferon In melanoma (high risk), A United Kingdom Co-Ordinating Committee On Cancer Research (UKCCCR) randomised study of observation versus adjuvant low dose extended duration interferon Alpha-2a In high risk resected malignant melanoma. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1393, 2001.